Elevance Health Inc. (ELV) — Fair Value Analysis

Base-case fair value (P50): $391.40 · Current price: $400.32 · Verdict: Fairly Valued

The Verdict on ELV

Our Monte Carlo simulations indicate Elevance Health (ELV) is Fairly Valued at its current market price. With ELV trading at $400.32, our median fair value (P50) analysis suggests a target of $391.40. This implies a nominal -2.2% difference from the current share price, positioning ELV comfortably within our fair value range after running thousands of forward-looking scenarios. Investors should note this tight alignment between market pricing and our probabilistic valuation.

How ELV stacks up against Healthcare

Elevance Health operates in the Healthcare sector, a segment often subject to specific regulatory and economic pressures. Our analysis places ELV in the average quality tier, reflecting its operational and financial health relative to its sector peers. Despite this average quality rating, the close proximity of its current trading price of $400.32 to our P50 fair value of $391.40 highlights market efficiency in pricing this particular Healthcare play. The -2.2% difference underscores the market's current agreement with our median probabilistic assessment.

What this means for investors

For investors considering ELV, the Fairly Valued verdict based on a median fair value of $391.40 against a current price of $400.32 suggests limited immediate mispricing. While a downside scenario is always possible, a bull case would require a shift in underlying fundamentals or market sentiment. The -2.2% figure emphasizes that, at present, our Monte Carlo analysis does not identify a significant edge for either bulls or bears at this price point. Sign up for a free FairCurve account to see the full bear/bull distribution and track ELV's fair value as new fundamentals are released.